HGH Fragment 176-191 (also known as "lipolytic fragment") is a synthetic peptide composed of amino acids 176-191 of human growth hormone (HGH). It has been specifically isolated and modified to preserve the fat-burning effects of HGH while eliminating broader systemic effects and potential side effects.

Main Benefits:

• Powerful lipolysis - breakdown and mobilization of stored fat

• Targeted reduction of adipose tissue (especially abdominal)

• Inhibition of lipogenesis (formation of new fat)

• Preserving muscle mass during weight loss

• Increased metabolic rate and energy expenditure

• Improvement in lipid profile (cholesterol and triglycerides)

• Hypoglycemic effects (reduction of blood glucose)

• Cartilage regeneration (when combined with hyaluronic acid)

• It does NOT affect tissue growth or insulin sensitivity.

• It does NOT cause hyperglycemia or insulin resistance.

• It does NOT increase IGF-1 or cell proliferation.

Typical Dosages:

Standard Dosage: 250-500 mcg, twice daily (subcutaneous)

Ideal Timing: Morning on an empty stomach + pre-workout or before bed.

Injection site: Abdominal adipose tissue (for better absorption)

Cycle duration: 8-12 weeks for optimal results.

Frequency: Daily during the active cycle.

HGH Fragment 176-191 works by increasing the formation of beta-3 adrenergic receptors (ADRB3) in adipose tissue, increasing the utilization and mobilization of fats. It stimulates lipolytic enzymes that break down triglycerides into free fatty acids and glycerol, without the anabolic effects of full HGH. It is particularly effective in obese rats, suggesting that it may be more effective in individuals with a higher percentage of body fat.

Advantages Over Full HGH:

• Specificity - only affects fat metabolism, with no broad systemic effects.

• Safety - does not cause acromegaly, edema, hypertension, or insulin resistance.

• Muscle Preservation - reduces fat without affecting muscle volume or mass.

• No Effect on Growth - does not stimulate excessive cell proliferation

Clinical Studies: A 2013 meta-analysis (Journal of Endocrinology and Metabolism) evaluated 6 studies and concluded that fragment 176-191 did not cause changes in glucose, insulin, IGF-1, thyroid function, or blood pressure when compared to placebo – confirming a superior safety profile to HGH.

Additional Therapeutic Potential: Research in cartilage regeneration (treatment of osteoarthritis), possible anti-angiogenic properties (inhibition of tumor growth in preliminary studies), treatment of pre-diabetes and type 2 diabetes.

Side Effects: Minimal - possible redness/swelling at the injection site, rare cases of fatigue or mild headaches.

Important Note: HGH Fragment 176-191 is NOT FDA approved for human use and is not regulated like full HGH. Based primarily on studies with AOD9604 (modified form). No direct clinical studies in humans have been conducted with pure fragment 176-191. Requires medical supervision.